AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21537720 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol plus midazolam
Number of subjects: 150
Study 21537720 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol alone
Number of subjects: 150
Study 19590476 — intervention group
Group type: EXPERIMENTAL
Intervention: G-ER 1800 mg once-daily administered in the evening
Number of subjects: 158
Study 19590476 — intervention group
Group type: EXPERIMENTAL
Intervention: G-ER 1800 mg asymmetric divided dose (600 mg AM and 1200 mg PM)
Number of subjects: 158
Study 19590476 — intervention group
Group type: COMPARATOR
Intervention: Placebo G-ER
Number of subjects: 158
Study 17044733 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg/day for 6 weeks
Number of subjects: 51
Study 17044733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 12929470 — intervention group
Group type: EXPERIMENTAL
Intervention: Per2/Ind0.625
Number of subjects: 235
Study 12929470 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg
Number of subjects: 235
Study 12929470 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 0.625 mg
Number of subjects: 235
Study 12929470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 11071065 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin treatment for 16 weeks
Number of subjects: 197
Study 11071065 — intervention group
Group type: COMPARATOR
Intervention: Xbal polymorphism
Number of subjects: 197
Study 11071065 — intervention group
Group type: COMPARATOR
Intervention: Ins/del and EcoRI polymorphisms
Number of subjects: 197
Study 9052620 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) group: five subconjunctival injections of 5 mg 5‐FU, starting from day 8 after surgery, one injection per week.
Number of subjects: 24
Study 9052620 — intervention group
Group type: COMPARATOR
Intervention: Control group: no injections.
Number of subjects: 24
Study 8448099 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-gauge Tuohy-Schliff needle/20-gauge catheter combination (group 1)
Number of subjects: 200
Study 8448099 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-gauge Quincke point needle/24-gauge catheter combination (group 2)
Number of subjects: 200
Study 8448099 — intervention group
Group type: COMPARATOR
Intervention: 22-gauge Quincke point needle (control group)
Number of subjects: 200
Study 3512898 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training (group 1)
Number of subjects: 80
Study 3512898 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy with biological feedback (BFB) (group 2)
Number of subjects: 80
Study 3512898 — intervention group
Group type: COMPARATOR
Intervention: No psychological influences (group 3, control)
Number of subjects: 80
Study 30940872 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCT protocol with 70 kVp, 16 mAs, and 180 µm voxel size
Number of subjects: 0
Study 30940872 — intervention group
Group type: COMPARATOR
Intervention: Ultra-low dose protocols with 400 µm voxel size and 7.4 mAs
Number of subjects: 0
Study 27392611 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluroshield
Number of subjects: 65
Study 27392611 — intervention group
Group type: EXPERIMENTAL
Intervention: Helioseal Clear Chroma
Number of subjects: 65
Study 27392611 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond + F
Number of subjects: 65
Study 27392611 — intervention group
Group type: EXPERIMENTAL
Intervention: Excite + H
Number of subjects: 65
Study 27392611 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sealant prevention
Number of subjects: 65
Study 25739317 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine voluntary deep-inspiratory breath-hold (VBH) technique
Number of subjects: 34
Study 25739317 — intervention group
Group type: COMPARATOR
Intervention: Free-breathing prone technique
Number of subjects: 34
Study 23930843 — intervention group
Group type: EXPERIMENTAL
Intervention: HFM-AB1 (500 ml antioxidant beverage 1; apple, grape, blueberry and pomegranate juices and grape skin, grape seed and green tea extracts)
Number of subjects: 14
Study 23930843 — intervention group
Group type: EXPERIMENTAL
Intervention: HFM-AB2 (500 ml antioxidant beverage 2; pineapple, black currant and plum juices)
Number of subjects: 14
Study 23930843 — intervention group
Group type: COMPARATOR
Intervention: HFM-PB (500 ml placebo beverage, free from fruit)
Number of subjects: 14
Study 22433978 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/d)
Number of subjects: 205
Study 22433978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 19581564 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 319
Study 19581564 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 319
Study 19581564 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose right unilateral ECT
Number of subjects: 319
Study 19581564 — intervention group
Group type: COMPARATOR
Intervention: Moderate-dosage bilateral ECT
Number of subjects: 319
Study 17353079 — intervention group
Group type: EXPERIMENTAL
Intervention: Siemens pulse oximeter (group S)
Number of subjects: 0
Study 17353079 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips pulse oximeter (group P)
Number of subjects: 0
Study 15037554 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide synthase inhibitor (L-NMMA)
Number of subjects: 18
Study 15037554 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 18
Study 15037554 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine (vasoconstrictor control)
Number of subjects: 18
Study 12147149 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin-glibenclamide 500 mg/2.5 mg
Number of subjects: 411
Study 12147149 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin-glibenclamide 500 mg/5 mg
Number of subjects: 411
Study 12147149 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 411
Study 12147149 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 411
Study 10372585 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-year health profiles, 27 empirical tests of independence
Number of subjects: 98
Study 10372585 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-year health profiles, 15 additional tests designed to be more sensitive to independence violations
Number of subjects: 98
Study 8848192 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective anesthesia of the right hemisphere during right intracarotid barbiturate infusion
Number of subjects: 20
Study 8848192 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 20
Study 2362257 — intervention group
Group type: COMPARATOR
Intervention: 4-6 cups filtered coffee per day
Number of subjects: 107
Study 2362257 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-6 cups boiled coffee per day
Number of subjects: 107
Study 2362257 — intervention group
Group type: EXPERIMENTAL
Intervention: No coffee at all
Number of subjects: 107
Study 373992 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% bufexamac cream
Number of subjects: 72
Study 373992 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% betamethasone valerate cream
Number of subjects: 72
Study 373992 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 72
Study 31174974 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial lactate level > 3.2 mmol/L and clearance of <20%
Number of subjects: 100
Study 31174974 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous lactate concentrations
Number of subjects: 100
Study 31174974 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial lactate concentrations
Number of subjects: 100
Study 31174974 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate clearance
Number of subjects: 100
Study 30401602 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral carbohydrate solution (OCS) administration
Number of subjects: 100
Study 30401602 — intervention group
Group type: COMPARATOR
Intervention: Control group (no food or drink before surgery)
Number of subjects: 100
Study 29017451 — intervention group
Group type: EXPERIMENTAL
Intervention: FilmArray® POC testing (intervention)
Number of subjects: 545
Study 29017451 — intervention group
Group type: COMPARATOR
Intervention: Routine, laboratory-based RP PCR testing (control)
Number of subjects: 545
Study 25494658 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil (EO) mouthrinse (40 mL/day for 90 days)
Number of subjects: 120
Study 25494658 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse (40 mL/day for 90 days)
Number of subjects: 120
Study 24070431 — intervention group
Group type: EXPERIMENTAL
Intervention: DPV 0.05% gel
Number of subjects: 48
Study 24070431 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo gel
Number of subjects: 48
Study 24070431 — intervention group
Group type: COMPARATOR
Intervention: Universal placebo gel
Number of subjects: 48
Study 21933896 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 35) managed by a diabetes centre with specialized management via a primary health-care nurse using a PDA-type blood glucometer
Number of subjects: 71
Study 21933896 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 35)
Number of subjects: 71
Study 21933896 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 36)
Number of subjects: 71
Study 21933896 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study 19336551 — intervention group
Group type: EXPERIMENTAL
Intervention: BRCAPRO model
Number of subjects: 3
Study 19336551 — intervention group
Group type: EXPERIMENTAL
Intervention: BOADICEA model
Number of subjects: 3
Study 19336551 — intervention group
Group type: EXPERIMENTAL
Intervention: Both models
Number of subjects: 3
Study 17691076 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (200-800 mg/d)
Number of subjects: 377
Study 17691076 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (5-20 mg/d)
Number of subjects: 377
Study 15015012 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease patients
Number of subjects: 51
Study 11174228 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (50 mg)
Number of subjects: 100
Study 11174228 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine alone (Control)
Number of subjects: 100
Study 9744776 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose carboplatin (Calvert formula based on 24-h Ccr)
Number of subjects: 52
Study 9744776 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose carboplatin (CG-Calvert formula)
Number of subjects: 52
Study 9744776 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose carboplatin (Chatelut formula)
Number of subjects: 52
Study 9744776 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose carboplatin (Calvert formula based on 24-h Ccr)
Number of subjects: 52
Study 9744776 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose carboplatin (CG-Calvert formula)
Number of subjects: 52
Study 9744776 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose carboplatin (Chatelut formula)
Number of subjects: 52
Study 9744776 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose carboplatin (AUCs aiming for target AUCs of 5 and 6 mg x min/ml)
Number of subjects: 52
Study 7794302 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 800 mg/d
Number of subjects: 271
Study 7794302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study 2929556 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.3 mg
Number of subjects: 6
Study 2929556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31538430 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term exposure to PM10 exceeding 100 µg/m3
Number of subjects: 0
Study 31538430 — intervention group
Group type: EXPERIMENTAL
Intervention: Very short-term exposure to PM10 exceeding 100 µg/m3 for 2 hours
Number of subjects: 0
Study 31538430 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term exposure to PM2.5 exceeding 50 µg/m3
Number of subjects: 0
Study 31538430 — intervention group
Group type: EXPERIMENTAL
Intervention: Very short-term exposure to PM2.5 exceeding 50 µg/m3 for 2 hours
Number of subjects: 0
Study 31538430 — intervention group
Group type: EXPERIMENTAL
Intervention: PM10 exposure on the 24-hr event day
Number of subjects: 0
Study 31538430 — intervention group
Group type: EXPERIMENTAL
Intervention: PM2.5 exposure
Number of subjects: 0
Study 28558817 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise, strength training, and physical therapy (3 months, biweekly 90-min sessions)
Number of subjects: 24
Study 28558817 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 24
Study 28558817 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise, strength training, and physical therapy
Number of subjects: 24
Study 28558817 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 25945691 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid group (CG)
Number of subjects: 100
Study 25945691 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (PG)
Number of subjects: 100
Study 21996417 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin/Ezetimibe combination
Number of subjects: 1563
Study 21996417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1563
Study 22086108 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal micronized natural progesterone (200 mg daily)
Number of subjects: 83
Study 22086108 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only tocolysis
Number of subjects: 83
Study 22086108 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 83
Study 19926893 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg daily)
Number of subjects: 81
Study 19926893 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg daily)
Number of subjects: 81
Study 19926893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 16376845 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision-suture
Number of subjects: 125
Study 16376845 — intervention group
Group type: COMPARATOR
Intervention: Resection-anastomosis
Number of subjects: 125
Study 16376845 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 125
Study 15103431 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating stimulation of real acupoints (Liv3 and G40)
Number of subjects: 15
Study 15103431 — intervention group
Group type: COMPARATOR
Intervention: Non-rotating stimulation of real acupoints (Liv3 and G40)
Number of subjects: 15
Study 15103431 — intervention group
Group type: COMPARATOR
Intervention: Stimulation of sham point (non-rotating and rotating)
Number of subjects: 15
Study 10930686 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Russian live attenuated and US inactivated trivalent influenza vaccines
Number of subjects: 614
Study 10930686 — intervention group
Group type: EXPERIMENTAL
Intervention: Live vaccine alone
Number of subjects: 614
Study 10930686 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated vaccine alone
Number of subjects: 614
Study 10930686 — intervention group
Group type: EXPERIMENTAL
Intervention: Live vaccine (alone or in combination with inactivated vaccine)
Number of subjects: 614
Study 10930686 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination vaccines
Number of subjects: 614
Study 9031444 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (Fragmin) 5000 i.u. once daily for 4 weeks
Number of subjects: 308
Study 9031444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study 8081065 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D3 supplements (1.2 g calcium and 800 IU vitamin D3 daily)
Number of subjects: 3270
Study 8081065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3270
Study 2577253 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 80 micrograms
Number of subjects: 45
Study 2577253 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 50 micrograms
Number of subjects: 45
Study 2577253 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 45
Study 319956 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% miconazole nitrate lotion
Number of subjects: 30
Study 319956 — intervention group
Group type: COMPARATOR
Intervention: Placebo lotion
Number of subjects: 30
Study 319956 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% miconazole nitrate lotion (for therapeutic failures)
Number of subjects: 30
Study 31222319 — intervention group
Group type: COMPARATOR
Intervention: Alg (1% microalgae, no additional choline chloride)
Number of subjects: 56
Study 31222319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ch0.1 (Alg plus choline chloride at 0.1%)
Number of subjects: 56
Study 31222319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ch0.2 (Alg plus choline chloride at 0.2%)
Number of subjects: 56
Study 31222319 — intervention group
Group type: COMPARATOR
Intervention: Control (0% microalgae)
Number of subjects: 56
Study 28553726 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational module for Latino parents about the health effects of sweet beverages
Number of subjects: 0
Study 28553726 — intervention group
Group type: COMPARATOR
Intervention: Control module
Number of subjects: 0
Study 26765317 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation treatment (ADT)
Number of subjects: 915
Study 26765317 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor Eastern Cooperative Oncology Group performance status (PS)
Number of subjects: 915
Study 26765317 — intervention group
Group type: EXPERIMENTAL
Intervention: High analgesic consumption
Number of subjects: 915
Study 26765317 — intervention group
Group type: EXPERIMENTAL
Intervention: Low hemoglobin
Number of subjects: 915
Study 26765317 — intervention group
Group type: EXPERIMENTAL
Intervention: High Soloway score (extent of disease observed on the scan)
Number of subjects: 915
Study 26765317 — intervention group
Group type: COMPARATOR
Intervention: Age, treatment, cardiovascular comorbidity, T category, grade of malignancy, serum estrogen level, and SHBG at enrolment
Number of subjects: 915
Study 23740357 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplanar reconstruction computed tomography (CT)
Number of subjects: 44
Study 21906903 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered balloon-expandable stent
Number of subjects: 125
Study 21906903 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent
Number of subjects: 125
Study 19553072 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating-platform (RP) prosthesis
Number of subjects: 140
Study 19553072 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing (FB) prosthesis
Number of subjects: 140
Study 19553072 — intervention group
Group type: COMPARATOR
Intervention: Both FB and RP prostheses
Number of subjects: 140
Study 17116004 — intervention group
Group type: EXPERIMENTAL
Intervention: Double‐blind treatment with metoprolol
Number of subjects: 809
Study 17116004 — intervention group
Group type: EXPERIMENTAL
Intervention: Double‐blind treatment with verapamil
Number of subjects: 809
Study 15574098 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Static Stretch (PSS)
Number of subjects: 97
Study 15574098 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Static Stretch (ASST)
Number of subjects: 97
Study 15574098 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Dynamic Stretch (ADS)
Number of subjects: 97
Study 15574098 — intervention group
Group type: EXPERIMENTAL
Intervention: Static Dynamic Stretch (SDS)
Number of subjects: 97
Study 11223708 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial thermal balloon ablation under local anesthesia
Number of subjects: 93
Study 11223708 — intervention group
Group type: COMPARATOR
Intervention: Endometrial roller ball ablation under general anesthesia
Number of subjects: 93
Study 8688774 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexamethasone 0.15 mg/kg
Number of subjects: 100
Study 8688774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 1747553 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive education group
Number of subjects: 104
Study 1747553 — intervention group
Group type: COMPARATOR
Intervention: Usual education group
Number of subjects: 104
Study 7037048 — intervention group
Group type: EXPERIMENTAL
Intervention: Complan meal (2.1 MJ)
Number of subjects: 16
Study 7037048 — intervention group
Group type: EXPERIMENTAL
Intervention: Complan meal (4.2 MJ)
Number of subjects: 16
Study 7037048 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (0.25 mg/kg)
Number of subjects: 16
Study 7037048 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (0.50 mg/kg)
Number of subjects: 16
Study 7037048 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 16
Study 7037048 — intervention group
Group type: COMPARATOR
Intervention: Water control
Number of subjects: 16
Study 30802186 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT)
Number of subjects: 97
Study 30802186 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus length (measured using susceptibility vessel sign on T2* imaging)
Number of subjects: 97
Study 30802186 — intervention group
Group type: EXPERIMENTAL
Intervention: Susceptibility vessel sign length
Number of subjects: 97
Study 27362838 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of reduced loneliness
Number of subjects: 60
Study 27362838 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of increased loneliness
Number of subjects: 60
Study 27362838 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60
Study 26170627 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesinurad (oral solution) 5 mg to 600 mg (single ascending dose)
Number of subjects: 66
Study 26170627 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesinurad (oral solution or immediate-release capsules) 100 mg to 400 mg once daily for 10 days (multiple ascending dose)
Number of subjects: 66
Study 26170627 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesinurad (tablets or capsules)
Number of subjects: 66